BioMedNewsBreaks

MondayJul 06, 2026 12:51 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition 

Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate ("ADC") technologies.   The latest transaction adds to a growing list of multibillion-dollar ADC and T-cell engager ("TCE") deals, highlighting continued strategic investment in differentiated antibody platforms.  VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology's most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The latest example came this week as Novartis agreed to acquire Myricx Bio for $1.1 billion upfront, plus up to $400 million in milestone payments, to gain access to the company's novel N-myristoyltransferase inhibitor ("NMTi")…

Continue Reading

MondayJul 06, 2026 9:20 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate ("ADC") programs and two non-BiTAC assets available for partnering. VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. Company…

Continue Reading

ThursdayJul 02, 2026 10:21 am

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program 

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ("BiTAC-TCE") program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. The collaboration follows encouraging preclinical data presented at the 2026 American Association for Cancer Research ("AACR") Annual Meeting and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies. VERAXA said its BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into…

Continue Reading

WednesdayJul 01, 2026 9:30 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Announces Term Sheet for CAD$5 Million Private Placement

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced it has executed a term sheet with arm's-length institutional investors for a previously announced non-brokered private placement with a notional subscription amount of approximately CAD$5 million. The offering will consist of 6,764,070 units at a notional price of CAD$0.7392 per unit, with each unit comprising one common share and one common share purchase warrant, and is expected to close on or about July 15, 2026, subject to customary conditions and regulatory approvals. The company said proceeds from the…

Continue Reading

WednesdayJul 01, 2026 9:00 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advances ONC010 Manufacturing Development With Nanosoft

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced the initiation of polymer process development and analytical characterization activities by Nanosoft Polymers in support of ONC010, the company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase inhibitor. The work includes polymer synthesis optimization, characterization methodology development, molecular weight assessment, purification strategy refinement and manufacturing scalability assessments as part of Onco-Innovations' chemistry, manufacturing and controls strategy. The company said the activities are intended to establish a scalable, reproducible and analytically characterized polymer platform to support future formulation, manufacturing, regulatory and clinical…

Continue Reading

TuesdayJun 30, 2026 2:08 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans

Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence. The company discussed innovative approaches to cardiovascular disease prevention, risk assessment and cost management at multiple national benefits conferences this month. Cardio’s presentations highlight how advanced cardiovascular risk assessment and detection tools can support both improved health outcomes and more effective healthcare cost management. “The company’s message centers on the idea that earlier identification of cardiovascular risk and disease can potentially enable more targeted interventions and preventive care. Rather than waiting until symptoms develop or major events occur, employers and health plans may benefit from…

Continue Reading

TuesdayJun 30, 2026 9:30 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study

HeartBeam (NASDAQ: BEAT) announced it has completed patient enrollment ahead of schedule in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The study enrolled 120 patients presenting with chest pain at two clinical sites in Belgrade, Serbia, with participants evaluated using both a standard 12-lead ECG and the company's 3D ECG technology. Data analysis is underway, and HeartBeam plans to present the results at a major cardiology conference later this year. The company said the study results are expected to support discussions with the FDA on the design of a planned U.S. pivotal trial and a…

Continue Reading

MondayJun 29, 2026 11:44 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Validation of Deciparticle(TM) Platform 

Oncotelic Therapeutics (OTCQB: OTLC), together with Sapu Nano, announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences validating its proprietary Deciparticle(TM) nanoparticle platform through the development of Sapu003, an investigational intravenous everolimus formulation currently being evaluated in an ongoing Phase 1b clinical trial. The publication details the platform's formulation design, scalable cGMP manufacturing process, product stability and preclinical performance, while demonstrating its potential to enable intravenous delivery of poorly water-soluble therapeutic compounds. The company said the research also supports broader applications for the Deciparticle(TM) platform beyond everolimus, including additional hydrophobic drug candidates. Sapu003 is currently being evaluated in a Phase 1b dose-escalation study in patients with advanced mTOR-sensitive solid tumors…

Continue Reading

MondayJun 29, 2026 9:10 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches AI Agent Platform for Patient Scheduling and Care Coordination

HealthLynked (OTCQB: HLYK) announced the launch of its next-generation AI Agent Platform, a conversational voice AI solution designed to automate patient scheduling, care coordination and healthcare communications for both patients and providers. The platform supports inbound and outbound voice interactions, enabling AI agents to schedule appointments, navigate physician office phone systems, collect patient and insurance information, perform intake functions, confirm appointments and provide 24/7 answering services for healthcare practices. The company said the platform is designed to help physician practices, accountable care organizations, health systems and insurers improve patient access while reducing administrative burdens and staffing requirements. HealthLynked plans a phased…

Continue Reading

FridayJun 26, 2026 2:22 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Analytics Beyond Traditional Screening

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection. The company was featured in a recent article that discussed its efforts to broaden the scope of its platform with the development of a fatigue prediction model designed for high-risk workplace environments. “The fatigue detection capability is expected to become an additional feature within MindBio’s planned Edge AI Intoxication Detection Kiosks, which are being designed to identify signs of alcohol, drug impairment and fatigue from short voice…

Continue Reading